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A B S T R A C T
BACkgRound: Anemia is a universal finding among ICU patients. It extends below 
traditionally accepted lower accepted limits for common ward patients and is only 
moderately counterbalanced with transfusions. To save red blood cell units, the no-
tion of low threshold was introduced. Beginning from the ICU patient population, the 
threshold strategy at the level of 7 g/dl is encouraged now to be generally investigated 
and applied.
oBjeCTive: A reappraisal of major papers was undertaken with the purpose to ex-
amine legitimacy of current restrictive transfusion strategy generalization dynamics.
MeThodS: One to one critical revisit is selected for specific influential papers. Ef-
fort is made for a delineation of individual paper characteristics and subsequent data 
incorporation into a structural scheme proposal with sole purpose to land on a ro-
bust evidence estimation. The authors insist on issues of perception and stand on the 
reader’s side instead of that of a writer or a member of a peer review team.
ConCluSion: Settling at threshold of 7g/dl seems well supported but not definitely 
proven for ICU patients. Lower values for hemoglobin need not be discussed for the 
time being, since this level is already extremely austere. Results in this group should 
not be perceived as readily generalizable to common ward or outpatients, as they be-
come achievable with simultaneous detailed monitoring and intensive functional sup-
port.
A .  i n T R o d u C T i o n 
There is nothing as good as pure blood when an indication for transfusion exists. 
In turn, blood is not regularly produced in a factory, so it must be thoughtfully col-
lected out of alive volunteering persons. Blood resources utilization comes therefore 
to be a courteous administrative challenge. To transfuse means to infuse viable tissue 
elements in the circulatory system of the patient. Seen this way, administrating blood 
units simulates transplantation. Although standardization in procedures and products 
is strongly desirable, full automation in clinical decision making about need for trans-
fusion is improper. On the other hand, full individualization of transfusion strategy 
could be perceived as proper and even desirable, yet it is not realistic. It may also be 
deceitful as a doctor’s promise and vain as a patient’s expectation. Clearly, we need 
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modern techniques and policy standards for this frequently 
needed and conducted procedure.
Fundamentally, indications must be documented and reac-
tions recorded as thoroughly as possible.1 Hospital Transfusion 
Committees may undertake a supervisory role, but the real 
challenge is the co-operation of the Blood Bank with clini-
cal departments. Departments need a common language to 
facilitate communication reciprocity. Thresholds as commonly 
accepted triggering values for transfusion appertain to this. 
Intensive Care Unit (ICU) remains attractive for safe clinical 
investigation including that for transfusion thresholds, as it 
makes use of multidisciplinary modalities for parameterization 
and timely intervention.
Anemia is very common in critically ill patients. Pathophys-
iology is multifactorial and multistage, whereas morphology 
is that of anemia of chronic disease.2 It could be presented as 
an acute and threatening form of anemia of chronic disease. 
Hemoglobin value has been used for staging as it relates to 
DO2 and is an easily obtainable and communicable number.3 
Anemia, as expressed by hemoglobin values, has often been 
related in literature with worse overall prognosis. This is very 
confounded as a result because of incongruous retrospective 
data use in metanalyses and additional alteration by accom-
panying transfusions.4 
To avoid irrelevant interpretations, some aspects of the 
critical anemia issue must be elucidated. First, severity of 
disease as depicted in Acute Physiology and Chronic Health 
Evaluation II (APACHE II), which is remarkably unique 
among ICU disease severity scores for incorporating anemia 
grading, is defectively estimating this special aspect of illness, 
as the vast majority of patients in the ICU according to this 
system would be uniformly given two points for an hematocrit 
of 20-29,9%.5 Second, the depth of anemia is going deeper 
than values considered decisive in perioperative fields.4 Third, 
orientation of ICU efforts points to maintenance of oxygen 
consumption for the sake of aerobic metabolism and this has 
also other ways to be pursued (e.g. ventilation and circulation 
assistance). Obviously, Hb and DO2 are not so directly related 
in circumstances like this.3 Last but not least, hematocrit res-
toration in near normal levels in the critical illness context is 
in reality unachievable, whatever the number of units utilized. 
In fact, satisfactory responses to transfusion rather point to the 
patient surpassing the critical stage of disease.6
Transfusion has been studied more efficiently than anemia 
in conjunction with mortality.7 Results tend to be different 
between surgery and ICU studies.8 Although surgical patients 
seem to enjoy overall benefit, ICU patients take only short-
term advantage. Lack of uniformity of results allows for many 
meta-analyses which tend to favor the notion that regular 
transfusion accompanies worsening of hospital outcomes.9 
Doubts about efficacy, partial futility, influence on out-
come and even necessity of transfusion since other oxygen 
delivery improving manipulations are available have led inten-
sivists to accept in principle the attitude of posing low cut-offs 
to hemoglobin values as a prerequisite for transfusion. The 
ICU has therefore become the leading research department 
for the substantiation of the transfusion threshold concept. 
Besides quantity of transfusions, their quality has been set 
under investigation also. Leucoreduction has been found to 
be helpful10 if applied on a wide basis and age of blood used 
seems not to be crucial when it lies in usual storage range.11 
Transitivity in methods of clinical approving transfusions 
and blood bank practices during the last twenty years has made 
post hoc recapitulation of study data necessary for a reader to 
shape an opinion. This will be attempted below, focusing on 
the clinical use of thresholds.
B .  M A i n  T h e M e
1 .  C u R R e n T  g u i d e l i n e S
The basic scheme proposed by the British Society for 
Hematology (BSH),12 based on all available information until 
2013 is given in figure 1. 
FiguRe 1. Guidelines by BHS-JPAC.
2 .  P l A i n  v i e w  o F  PA P e R S 
a. Transfusion Requirements in Critical Care- TRICC 
trial
design: The fundamental study involving critically ill 
patients is the TRICC (Transfusion Requirements in Critical 
Care, TRICC) trial by Paul Hebert et al for the Canadian Criti-
cal Care Trial Group in 1999.13 Even now it is the only multi-
center trial exploring this subject for general ICU population. 
The trial was conducted in 25 Canadian hospitals from 1994 to 
1997. The presence of anemia with euvolemia and anticipated 
ICU stay of more than 3 days constituted the inclusion criteria. 
Intravascular volume was monitored and optimized by the 
intensive care unit specialized personnel. Exclusion criteria, 
besides null expectation for survival and preexistent anemia, 
consisted of the absence of active bleeding and cardiac surgery 
admission. Patients were divided into 2 groups: the restricted 
one with transfusion threshold of 7mg/dl and hemoglobin 
maintenance between 7-9g/dl and the liberal one with trans-
fusion threshold of 10 mg/dl and hemoglobin maintenance 
between 10-12g/dl. Randomization included stratification 
for acute physiology and chronic health evaluation score 
(APACHE 2 score) and hospital, with further restriction to 
permuted blocks within strata. Central co-ordination consisted 
of generating random numbers in blocks of 4 to 6 in double 
for every hospital, enclosing the numbers in sealed envelopes, 
distributing the envelopes to centers and receiving periodically 
returned envelopes for inspection. 
outcomes and results: Death from any cause at 30 days 
was the primary outcome. Death at 60 days, death in hospital, 
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death in ICU, duration of hospitalization, length of ICU stay 
and quantitative measures of organ dysfunction were all sec-
ondary outcomes. 838 patients were randomized. Analysis was 
conducted by the intention to treat principle (ITT). Baseline 
characteristics were similar in the two groups and pointed 
to patients of at least moderate severity as >80% were con-
nected to a ventilator and the mean APACHE 2 score was 21. 
Primary outcome did not show any difference between groups. 
Adjusted organ dysfunction scores and their alteration during 
ICU stay were better for the restriction group. Subgroup analy-
sis disclosed an advantage in 30-day survival of the restrictive 
policy for young (<55 years) and milder illness populations 
(APACHE score II <20). Subgroups of patients with sepsis, 
trauma14 or cardiovascular problems15 behaved much the same 
irrespectively of group. 
Comments: Issues arise about the statistical power and the 
quality of inference. TRICC was designed as an equivalence 
trial, that is, to show that restriction of transfusions would lead 
to a mortality result not more or less than 4% (2% on each 
side), compared to the 30-day mortality of the standard liber-
ally transfused group, which was thought optimistically to be 
20%. Bioequivalence as a design is mainly used in laboratory 
drug studies. From the outset it could be commented that 
equivalence is an ambitious target as it is oriented towards 
the lack of not a simple arithmetic but a standardized dif-
ference between the control and intervention groups. As 
such, it essentially makes use of bidirectional one-sided tests 
that determine the upper and lower boundary of confidence 
intervals. This is more demanding than relying on solitary 
one-sided or two-sided tests.16 For this reason, sample power 
needed is the most sizeable compared to relevant statistical 
choices (non inferiority or superiority trials). The sample size 
depends on the selected percentage (lower deviation means 
greater sample, most influential), the rate of success of the 
standard trial arm of study (the greater this rate the greater 
the sample, less powerful influence), the combination of the 
above two and conventions for statistical errors. 
The basic notions are: a) the null hypothesis is that the 
two treatments are different.17 This is the opposite of the 
usual case. b) type 1 error is to reject this hypothesis when the 
FiguRe 1. Directions from BHS and JPAC (10), 2013 [permission for use given].
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To find in the end a low mortality is more serious because it 
uncovers a better sample quality, able to endure treatments 
of doubtful benefit. Still, both help to ease the job of equaliza-
tion, since both tend to obscure benefit from the traditional 
generous liberal approach to transfusions.
But there is more. The standard arm here is the liberal 
strategy arm and the 23% percentage found is greater than 
the 18% percentage of death in 30 days found in the restric-
tive arm. The interim analysis was not preprogrammed and 
was probably propelled by safety worries. difference between 
arms instead moved to the opposite direction than initially 
thought. Seemingly, this contrast created an impression of 
de facto equivalence. Investigators could have thought that 
this inverted difference between arms was not anymore in 
need of full empowerment to refuse the null hypothesis. 
This is something although that can’t be declared officially. 
The study is said to have been stopped prematurely merely 
because of recruitment flow deceleration. Published p values 
for outcomes rather portray a quasi successful superiority trial 
in favor of transfusion restriction than the technical incapacity 
to decline the null hypothesis of difference in the context of 
an equivalence trial. Definitely, the sample size utilized makes 
us unable to recognize real similarity, because we are prone 
to find similarity everywhere due to obvious and unscheduled 
expansion of b-error and loss of statistical power. 
Looking forward now, whenever a great lag between 
assessment and final inclusion is ascertained, we use to talk 
about compromised generalization potential. This is not fair 
for this case even in the context of the aforementioned statisti-
cal shortfall. Whatever patient is left behind, looks very much 
like the everyday life of the average ICU. The randomized 
population of patients is absolutely representative as it is 
numerous, of moderate severity, general in nature with all 
subgroups proportionally participating. The eligible person’s 
profile was so clearly delineated, that grey zones were totally 
obstructed. Reasons of eligible population for non-entry to the 
study were free of bias as to the final result. Primary outcome 
recorded was unmixed and the only worth. We come to agree 
with the authors that findings can be readily generalized, as 
there is a respectable number of 838 patients and an impec-
cable distribution. 
First hypothesis formation is acceptable in the field of 
mathematics in the face of full uncertainty. TRICC is a valuable 
piece of naïve clinical investigation as its primal question is both 
daring and simple. It is also technically exemplary for its high 
level of achieved corroboration. Clinical constraint impeded 
statistical integration, but this is not to blame but to admire 
because it accompanies the trustworthiness of excellent clini-
cal conduction. But at the end of the day, it remains clinically 
safer to state that restrictive and liberal policies are different 
when they really are the same than to accept identity when the 
two arms are in fact different. We could well cope with a slight 
allowance towards the first direction but not with the second.
hypothesis is true, i.e. to argue that restricting transfusions is 
the same with liberal policy although that they are different 
in reality. This type is represented by p which in clinically ori-
ented studies should be preserved to the usual 0,05 (instead 
of using p=0,10, which happens quite often in bio-equivalence 
trials), c) Type 2 error is to accept the null hypothesis when 
the hypothesis is false, i.e. to say that restricting policy is dif-
ferent than the liberal, when in reality they are the same in 
terms of mortality. This probability, which usually is confined 
to 20% and is a major determinant variable in sample size 
calculation is not mentioned across the whole paper. Instead, 
an interplay between targeted margin and baseline mortality 
is recorded. After an intermediate adoption of sample size of 
1620 patients and difference of the 5,5% class, it settles the 
type 2 error below 50%. 
What could be a correct margin of equivalence in such a 
study? The reasonable approach is to select a number which is 
related to the treatment result of the standard arm itself. The 
problem is that equivalence studies do not generally have a 
placebo group which would naturally function as a reference, 
so literature data are used instead.17 In this case, not only 
control completely without transfusion would not be allowed 
either way for ethical reasons, but also relevant literature is 
lacking. Since there are no data to substantiate the improve-
ment brought upon by transfusions for patients, the percentage 
chosen to be ruled out as a difference was already arbitrary. 
Soon it became also elasticated. 
Simultaneously the mortality of the standard arm became 
puzzling. More specifically, the initially hypothesized baseline 
mortality of 20%, was in an interim analysis of 404 patients 
proved to be arithmetically 23%. Could such a little deviation 
be a source of trouble? An automatic calculator would charge 
about 180 more patients every arm to show the 4% margin. 
Moreover, looking back, numbers from initial assessment 
(6451 patients) to final randomization (838 patients) seem to 
collapse. From 6451 assessed, only 3206 are found eligible. 
Reasons for non-eligibility include active bleeding, chronic 
anemia but there is also a remarkable number of 818 patients 
who were deemed to stay in the ICU less than 24 hours. This 
is not very common in general ICU’s of many countries, as 
the context of work is not always anesthesiologic. From 3206 
patients, the number shrinks to 2039 for various rather ad-
ministrative or blood bank-imposed reasons. And after that, 
1201 refusals are conceded, either from the physician’s or the 
family side, balanced between each other, which is absolutely 
reasonable in view of the entrepreneurial nature of the whole 
process. On such a subsiding ground, slight numerical depar-
tures from expected control mortality can truly derail sample 
size issues, both as to quality and quantity. 20 to 23% increase 
could prove finally serious enough. Further on, the estimation 
remains optimistic since an APACHE II score of 20-22 degrees 
corresponds to a mean hospital mortality 30-40%. To predict a 
low baseline mortality initially moderates sample size demands. 
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Statistics are not TRICC’s leverage, since clinical con-
cerns have been more influential for its course. The trial is 
inadequately empowered to carry equivalence along. It is 
nevertheless the main study that contributes an important 
amount of data in meta-analyses, because one of its excellent 
characteristics is that it volunteers for future coalescence with 
other studies. According to older and more conservative per-
ceptions about grades of evidence and recommendations, even 
if this trial would have come to a statistical end, the need for 
another confirming trial would still hold. More recently, level 
1 evidence is achieved with only one randomized control trial 
with statistical completeness or systemic review of individual 
homogeneously targeted randomized trials.18 The discussion 
below deals exactly with TRICC’s awaited sequel.
b. Add-ons to TRICC: neurologic, pediatric and sepsis 
populations
Subgroups behaved much the same in TRICC trial. This 
was initially thought to mirror the relatively stable situation 
of the patients, e.g. what the authors mentioned as euvolemic 
patients. In essence, these were patients in the post-acute 
severity decelerating period, corresponding somewhere be-
tween the second or third phase of Pamplin’s Phases of Illness 
Paradigm, (POIP) of hospital course.19 Trauma patients need 
aggressive transfusion therapy when actively bleeding,20 but 
thresholds hold for the postoperative and ICU stage. Trau-
matic brain injury is a separate class which is examined many 
times together with ischemic brain damage.21 Data about brain 
damage have not changed. The major study about traumatic 
brain injury is that by Robertson et al22 (EPO Severe TBI 
study) with 200 patients and a factorial design for simultane-
ous study of erythropoietin usefulness. The study did not show 
any advantage for liberal transfusion thresholds in this special 
kind of trauma. Nevertheless, worries about sensitivity of nerv-
ous cell to the vicious cycle of hypoxemic insult and edema, 
have preserved a transfusion threshold of 8 mg/dl for critical 
neurologic disease.23 A new trial (ΗΕΜΟglobin Transfusion 
Threshold in Traumatic Brain Injury Optimization: The EMO-
TION trial, ClinicalTrials.gov Identifier: NCT03260478,24 with 
762 patients in Canada) has been now undertaken in order to 
provide awaited answers.
The TRIPICU25 trial by Lacroix et al, came to deal with the 
issue in Pediatrics. 627 children from 3 to 14 years old from 19 
hospitals in 4 well developed countries entered the flow of a 
non-inferiority design with 10% margin. The two approaches 
(thresholds of 7 vs 9g/dl as transfusion triggers) did not differ 
at all as to a composite outcome of death and occurrence or 
worsening of MODS. The overall incidence of the outcome was 
only 12% though and reference estimation is not mentioned. 
Divergent profiles of outcome frequency and icu admission and 
length of stay profile between children and adults makes meta-
nalytic mixing of results inappropriate. Separate convincing 
data are definitely needed for every group, especially for kids.
Regarding sepsis, the study by Rivers et al26 (Early Goal 
Directed Therapy-EGDT-Collaborative Group study) inter-
posed a threshold of 10mg/dl for the evolving septic shock, 
along with other interventions with fluids and inotropes. 
Rivers’ study did not mention assumed baseline mortality but 
the anticipated mortality benefit was 15%. The results stood 
between 46,5% (standard arm) and 30,5% (experimental 
arm). Sample size was from one center and it was only 260 
patients. It is tiny, especially bearing in mind the huge impact 
of forthcoming application. The whole tactic was challenged, 
although after 13 years, by newer trials in sepsis with more than 
1000 patients each.27-29 In the passage of time though, general 
application of protocols sticking to first-order manipulations 
in antibiotics and fluids is unfolded, leading to an upgrade of 
the whole emergency care context. In this evolutionary process, 
let us believe that the study by River and colleagues, beyond 
problems with single-center conduction and the absence of 
a reference mortality was fairly constructive. Naturally, the 
transfusion arm could nothing but change together with all 
other paths of the algorithm all the way through.
c. Transfusion Requirements in Septic Shock - TRISS 
study
The arrival at the section of transfusions in this setting is 
the study by Holst et al.30 
design: The study (Transfusion Requirements in Septic 
Shock, the TRISS trial), comes from 32 Scandinavian Hospitals 
between 2011 and 2013 and aims to confirm the restrictive 
policy concept for transfusion as well as to challenge the first 
6 hours issue, posed by River’s study. Randomization scheme 
included stratification for center and presence or absence 
of hematologic malignancy and permuted blocks of 6,8,10 
patients at 1:1 proportion. Blinding in all these studies cannot 
be perfect as doctors need to know the intervention. Inclusion 
criteria were age greater than 18 years, ICU admission, septic 
shock and Hb less than 9g/dl. Exclusion criteria included active 
hemorrhage and active coronary artery disease. The thresholds 
chosen were 7mg/dl for the restriction policy arm and 9mg/dl 
for the ‘standard’ arm. In contrast with TRICC, all red blood 
cell units were leucodepleted.
outcomes and results: Primary outcome chosen was 90-
day mortality. Inotrope and mechanical ventilation use at day 
5-14-28, complications, ischemic events, days free of support 
until the 90th day, days alive and out of hospital until the 90th 
day constituted secondary outcomes. 
Comments: This was a superiority trial, which is less de-
manding than equivalence in terms of sample size. Baseline 
mortality was taken as 45% and desired improvement was 
taken as 9%. Given these numbers, in Holst’s study, a power 
of 80% and p value of 0,05, sample size was calculated at the 
number of 1000 patients. Analysis was conducted according 
to ITT principle and was complemented by per protocol 
(PP) analysis as violations were more on the restrictive side 
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(45 vs 16 patients). An interim analysis was programmed 
for 500 patients. Study flow from assessment for eligibility 
to randomization and follow up was exceptionally tight with 
1224 assessed, 1005 randomized and 998 included in final 
analysis. Severity was rather mild to moderate and about 50% 
of patients belonged to medical wards and had respiratory 
infections. Mortality was as expected (43 vs 45%). No differ-
ence was found in any outcome or subgroup (age><75yrs, 
APACHE 2><53, cardiovascular disease). In principle, failing 
to reveal superiority does not mean equivalence in statistical 
terms. Moreover, violations of protocol were significant and 
necessitated an additional PP approach. This need is itself an 
issue because the usual analysis selection is the ITT, the PP 
results given only when in concordance. In other case, more 
statistical work-up is warranted and possible problems about 
publication arise. These violations concerned both allowing 
units to the restricted group and restricting units for the liber-
ally treated patients. The whole effect could well be a degree 
of mitigation. On the contrary, uniform use of leucodepleted 
products is an advantage since it isolates one of the confusing 
factors, enhancing possible transfusion benefits. 
Transfusion during the first 6 hours, a matter posed by Riv-
ers et al and supposed to be one of the questions that TRISS 
would explore, is not answered in reality, as all patients are 
seated in the ICU at randomization, and time data from the 
Emergency Department (ED) are not mentioned. Rather 
this issue has been overcome not by TRISS itself but by the 
synchronous constellation of studies targeted to the early care 
of sepsis.26,27 We do not know how many patients in TRISS had 
received rescue transfusion. In case this number was great, it 
could mitigate results even more, as what has been done in 
the first place seems to be decisive for whatever will follow. 
Transfusing to catch a decent hemoglobin value instead, is 
confirmed to be explicitly futile, as the majority of patients 
received over three red blood cell units in the liberal group, 
whereas most patients in the restrictive side consumed one 
or zero units. These findings, quoted in the supplementary 
appendix29 of the study, expose both mortality-hemoglobin 
dissociation and hemoglobin-transfusion intensity lack of 
proportional response. 
The compactness of this study is nearly beyond belief. 
Sepsis is a condition whose outcome is dependent more on 
the Health and Hospital system than on the patient himself. 
Even though percentage of mortality falls within the widely 
reported range, control of patients in all stages must have been 
very effective. This is a crucial obstacle to generalization since 
other countries suffer from prehospital and hospital system 
inadequacies. The time from TRICC to TRISS and beyond 
certainly has played a role, in terms not only of modification 
of standard care, but also intermediate consolidation of re-
strictive practice (in other words, de facto reconciliation to 
equivalence) and improvement of blood bank product quality. 
TRISS trial, although narrowly targeted, is the most relevant to 
TRICC in terms of their potential to merge with one another. 
d. Exclusions of TRICC
Building up confidence to the scientific significance of a 
study can be done in two ways. The first is to multiplicate it and 
directly confirm it, which is the traditional straight selection, 
exemplified as precisely as possible in the case of TRICC with 
TRISS and TRIPICU studies. An alternative is to surround it 
with data from excluded populations in the first study, which 
resembles a circumferential or marginal approach. Crudely, if 
the argument still holds in the feared case, it holds even more 
in the rule area. In words of reasoning, clarifying boundaries 
helps to elucidate concepts within. The two major excluded 
categories in TRICC were active bleeding and cardiac surgery. 
Recent studies venture into these territories. 
i. Acute Hemorrhage: 
Active bleeding is a recognized indication for transfu-
sion, something that is clearly mentioned in guidelines.12,31 
Surgical control of blood loss is fundamental in many cases. 
Transfusions are used in this life saving setting rather liberally 
in order to protect the operational conduction and result but 
are rationalized thereafter. To raise an argument in favor of 
transfusion restriction already at the outset means in principle 
to stay behind direct surgical interests.
The Villanueva (ESTudio RAndomizado y controlado 
de los requerimientos Transfusionales en la 
hemorragia digestiva alta aguda, ESTRAT) study 
design: The study by villanueva et al,32 is engaged in upper 
gastrointestinal bleeding, a situation used to be conservatively 
managed in the first place. The study was conducted in only 
one center in Barcelona between 2006 and 2009 and included 
921 patients. Acute coronary disease, lower gastrointestinal 
bleeding and patients with a great probability of re-bleeding 
or death as estimated by the Rockall score were excluded 
along with other typical exclusions. Transfusion thresholds 
and hemoglobin ranges chosen were 7-9g/dl and 9-11g/dl. As in 
all studies about transfusions, blinding could not be complete. 
Randomization scheme consisted of stratification according 
to presence of hepatic cirrhosis and use of blocks of 4. All 
patients received a first unit of red blood cells. The units were 
leucodepleted and had a mean hematocrit of 60% which is 
rather low. Treatment consisted of immediate endoscopy and 
local treatment with electrocautery, ligation or cyanoacrylate 
infusion and drug therapy with omeprazole or somatostatin. 
Some patients with cirrhosis underwent also hepatic venous 
pressure gradient measurement. 
outcomes and results: Primary outcome chosen was 45-
day mortality, whereas re-bleeding and complications were 
set as secondary outcomes. Design referred to a superiority 
trial, assuming 10% baseline mortality and 5% reduction by 
restrictive handling of transfusions. Analysis run according 
RED BLOOD CELL UNIT UTILIZATION IN THE ICU: EvIDENCE AND CONFIDENCE
13
to ITT principle and subgroups pre-specified concerned only 
presence or absence of cirrhosis. From 1610 patients assessed 
for eligibility 962 were confirmed as such and finally 921 were 
randomized. 49% had peptic ulcer and 31% had cirrhosis. 
Besides reduction in units given in the restrictive group, an 
advantage of restriction policy over standard manipulation ap-
peared (23 vs 41 patients). Re-bleeding, length of stay, rescue 
surgeries, hepatic venous pressure gradient and complications 
were all better in the restrictive group. 
Comments: This study is single centered and reflects 
mainly the clinical efficiency of the responsible team in this 
hospital. The baseline mortality was small as predicted and 
this facilitates fulfillment of sample size demands. Severely ill 
patients were excluded, which enables mortality to remain low. 
Even though the population of restriction group as a whole 
behaved better, the advantage is more profound on cirrhosis 
patients and implies involvement of specific mechanisms as 
hepatic venous pressure also indicates, like some form of circu-
lation impediment in visceral vein vasculature. The message is 
rather that transfusion for bleedings of upper gastrointestinal 
origin can be minimized, if indicated diagnostic and treatment 
interventions are provided in a timely and safe fashion. Un-
der certain circumstances like cirrhosis, volume or viscosity 
related challenge with transfusion may even be harmful. This 
is a motive-creating finding for the team in charge. Overall, 
it is the only study with pure mortality as a primary outcome 
that sets foot on superiority, but it pertains to patients outside 
the icu and thus its additivity to TRICC is questionable, as is 
also its repeatability on a multicenter basis. The Transfusion 
in Gastrointestinal bleeding (TRIGGER) trial33 is the sequel. 
It is a feasibility study with cluster design, undertaken as a 
precursor of a multicenter properly empowered study to reply 
to the repeatability and generalization to the hospital reality 
of the ESTRAT study. Whereas cluster design with counting 
on hospitals instead of patients as units of power, seemed to 
facilitate recruitment, homogeneity in emergency action during 
the first 6 hours across hospital proved problematic to achieve. 
Outcomes did not differ but results are only indicative.
Primal findings of endeavors like the above two studies, 
suggest that hemorrhage is not fully incompatible with some 
kind of transfusion economy, provided that hemostatic ma-
nipulations are well targeted, timely and adequate.
ii. Cardiac Surgery:
This is a field that yields dual concerns since it is applied 
at first to cardiovascular patients which subsequently, after 
the discrete surgical hit, fall into the critically ill category. Two 
large randomized studies dominate here at present:
1) Transfusion Indication Threshold Reduction -  
The TITRE-2 study
TITRE-2 study by Murphy et al34 came first to fill the gap. 
Baseline knowledge about use of red blood cell units in cardiac 
surgery is readily commented in the background. Whereas 
more than 50% of patients are transfused, the range of transfu-
sion frequency is extremely wide in pioneer countries such as 
UK and USA, which highlights that it is the availability of blood 
that matters more than performance of transfusions itself. 
design: This was a prospective multicenter study in 17 
hospitals in UK between 2009 and 2013 and included adult 
patients scheduled for elective surgery of several types. Sep-
tic and emergency patients were excluded. Randomization 
scheme consisted of detecting patients with postoperative 
hemoglobin value of 9 g/dl or less, and allocation according 
to cohort minimization which implies stratification according 
to centers and leads always to well balanced samples. Patients 
remained blinded. Selected thresholds were 7,5 and 9 g/dl, 
which were tougher than the previously used. Liberally treated 
patients received a single red blood cell unit as a bonus im-
mediately after randomization.
outcomes and results: The primary outcome was com-
posite, consisting of 90-day appearance of ischemic events 
and infections. Mortality here was a backstage secondary 
target along with length of stay, individual elements of the 
composite outcome, quality of life, adherence to protocol and 
cost. This study used conclusions of a previous study from the 
same contributors in 2007. Baseline acceptances were drawn 
from this former study and were 11% and 17% incidence of 
the outcome in the restrictive and liberal group respectively. 
From the sample size calculation, one can understand that 
this was conceived as a superiority study with 90% power, 
trying to declare the formerly shown difference as statistically 
important. There was no prediction for interim analysis. From 
8428 eligible patients, 3565 gave written consent and 2007 
were randomized from which the vast majority was included in 
analysis. Intention to treat principle was used in analysis. 63% 
patients of the restrictive group received at least one unit of 
red blood cells and 26% of patients received at least one unit 
before randomization. Severe non adherence was slightly more 
common in the restrictive group and not statistically checked. 
Results were surprising in that although the primary outcome 
affected the same percentage of patients (33 vs 35%), there 
were statistically more deaths in the restrictive arm (4,2 vs 
2,6% or 42 vs 26 deaths, p=0,045). 
Comments: The choice of outcome served the practical 
purpose of a more manageable size compared to mortality. 
Sensitivity analysis by adding acute kidney injury or subtracting 
patients transfused prior to randomization, further enhanced 
the distance between arms in favor of the liberal strategy. 
Remarkably, the centre with the greater contribution (382 
patients out of a total of 2003 patients, with usual numbers 
falling between 100-150 patients/centre) whose name is not 
mentioned, was the only one that gave clear results favoring 
liberal manipulation. Data assert that stinginess in transfusions 
is at least not superior to a liberal approach. One interesting 
comment about chosen thresholds is that by choosing 9g/dl 
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for the liberal arm, the investigators pushed 1288 patients out 
of study since they moved in higher hemoglobin values. Sup-
posedly the liberal threshold was defined in the order of 10g/
dl -as in other studies like Hajjar’s- this numerous population 
would have entered the study. The anticipated influence for 
such a mix experiment with good quality patients could have 
restrained mortality from becoming apparent. Now, trying to 
prove superiority and ending up with more mortality is defec-
tive and doubtfully repeatable as an attempt. 
2) Transfusion Requirements in Cardiac Surgery Trial 
– TRICS III study 
This study by Mazer et al35 was published in the end of 
2017, as an adequately powered answer to the Titre-2 study. 
design: this was an open-label multicentric study. It was 
supported by Canada and Australia Health Institutes for Blood 
Services and recruited participants from 79 hospitals settled 
in 19 countries from 2014 to 2017. It compared restrictive 
transfusional strategy with threshold Hb 7,5g/dl to the liberal 
option with transfusional threshold of Hb 9,5g/dl or 8,5g/dl 
(ICU or common ward respectively). Randomization took 
place before the operation and the resulting strategy was 
applied in the perioperative period too. Euroscore as a prog-
nostic inclusion criterion was set at 6 or more, which means a 
moderate to high surgical risk. A composite of death and other 
complications was defined as the outcome of interest. Baseline 
incidence was considered to be about 11% and sample power 
was calculated in a non-inferiority context with δ=3%, aiming 
at an one-sided a-error of 0,025 and a b-error of 85 initially and 
later 90%. Pilot TRICS II study patients were incorporated all 
along. Primal analysis was conducted by the PP methodology. 
Although randomization blocks were attributed to every site, 
no stratification according to centre in the context of primal 
analyses was used.
Results and outcomes: 5243 patients were randomized, 
5092 consisted the modified ITT population and 4860 were 
included in the PP analysis, which is a tight flow course. Primary 
outcome did not differ between groups, so non-inferiority was 
reached. Patients over 75 years were found to take a small 
advantage of transfusion restrictions whereas length of stay 
in ICU and hospital as well as delirium incidence were found 
to favor slightly the liberal group.
Comments: Statistical success is the first to admit after 
reading this study, as the sample was adequate to face mortality 
issues and initial acceptances were strict and realistic. Patients 
were plenty and sufficiently ill. The threshold of 9.5 g/dl for the 
liberal group has gathered many good quality patients inside, 
so maybe a soothering population mix, which was not present 
in Titre-2 has ensued. There is one comment that should be 
made. Hemoglobin move in values of 8.5 to 9.5 g/dl in both 
groups and all the stages of care which is importantly higher 
than the threshold of 7.5 g/dl which could according to working 
hypothesis jeopardize outcomes. Whereas this was also a fea-
ture in Titre-2, here the distance between the lower Hb tested 
in working hypothesis and that observed in the study is greater 
(approximately 8,5 and 8g/dl respectively). In comparison to 
Titre-2 study, here we have early randomization, much more 
patients, much more centers, greater euroscore, less overall 
transfusions though, probably less operational complexity, 
probably better functional status of patients, perioperative 
secondary outcomes description such as low output syndrome, 
shorter follow-up for primary outcome (28 vs 90 days) and no 
perioperative blood saving procedures description. Overcom-
ing the arithmetical issue, the presence of too many hospitals 
and discordance between euroscore prognostic evaluation and 
clinical data (predicted and observed mortality >6% and 3% 
respectively) raise an issue of selection bias. In the introduction 
of Titre-2, a comment is made about variations in transfusion 
rates. It is possible that TRICS-III took advantage of routine 
ambiguity about need for transfusion so that participation in 
a famous running study worked as an extra motive for respon-
sible personnel. Not refusing the attractiveness of a numerous 
sample, we support the case that Titre-2 was much more tight 
as it was conducted in a single country, achieve proportionally 
faster rates of patient recruitment and also was more consist-
ent with simple medical principles, like cautiousness about 
perioperative issues. To conclude, despite the presence of two 
multicentric studies, evidence for the special area of cardiac 
surgery has not been integrated yet.
e. The cardiologic case- Myocardial Ischemia  
and Transfusion (MINT) pilot study
Cardiac surgery patients’ manipulation cannot fall into 
core restrictive perceptions. They function rather as a signal 
for the wide cardiovascular category of patients for whom 
final conclusions have not been yet drawn. It’s again time to 
take a long jump entirely out of the ICU territory to identify 
exceptional patient characteristics and bring them back within. 
Carson et al have published a pilot study strictly focusing on 
the cardiac subject.36 
design: This was a pilot study with 110 patients from 8 US 
hospitals with stable or unstable coronary disease in the way 
to cardiac catheterization. Chosen thresholds for transfusion 
were 8 or symptoms restrictively and 10g/dl liberally. From the 
registration number we understand that this is the entryway 
to the MINT study (Myocardial Ischemia and Transfusion). 
Randomization included stratification according to center and 
stable or unstable disease and the use of blocks. The selected 
primary outcome was a composite of death, myocardial infarc-
tion or need for emergent revascularization in 30 days. Also, 
a number of other outcomes relating to mortality, ischemic 
events and complications were recorded. 
outcomes and results: Details about calculation of sam-
ple size are not given, but the pilot trial stopped early in 110 
patients and not 200 as initially planned, after the decision of 
the supervising committee. From 1920 assessed patients, only 
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110 were included, the reasons being mainly milder anemia, 
refusals, critical illness and need for emergency surgery. All 
patient entered analysis which was done by intention to treat. 
Leucoreduction was not a precondition, although it had been 
conducted finally in the vast majority. The age of red blood 
cells is one of the greatest in related studies. The flow of study 
revealed that the outcome happened more often in the restric-
tive arm (14 vs 6 pts, 25% vs 10%, p=0.054). Especially death 
with 1 in liberal and 7 events in the restrictive arm, proved to 
be also statistically significant. The trial was disrupted before 
the difference could become able to substantiate difference 
and the reason given was that it was decided to leave some 
space for other studies.
Comments: Timing of randomization in relation to cath-
eterization is not mentioned. Moreover, global conduction of 
catheterization on the same admission is not confirmed in the 
text. Age is greater in the restrictive arm. Patients in this arm 
had less often stable angina, had less often undergone PCI, 
had more 3-vessels disease and more anemia before transfu-
sions. In other words, it was a group with more severe health 
distortion and worse prognosis. Liberal patients maintained 
the value of 10g/dl arithmetically, whereas restricted patients 
had to express symptoms of fall to 8g/dl if it were to receive 
blood. In view of more severe disease and need for conserva-
tive treatment, the contrast between the generosity for the 
first and stinginess for the second group is provocative. Is this 
a protocol defect or a kind of clinical bias in order to protect 
interventional success? Surely anyway, is an adequate reason 
to pause the conduction of the study. 
Half the matter is about a single unit of blood as can be seen 
in the table of transfusional data. Thus allowing for one unit 
a priori, maintaining hemoglobin values above 8 g/dl regard-
less of symptoms, and having equalized disease severity and 
maximized revascularization in both groups would be fairer. 
Anemic patients are deeply ill in the coronary disease setting 
and probably more dependent on adequate hemoglobin. In 
view though of its weaknesses, MINT is an aggregate of well 
balanced between hospitals groups of patients, initialized and 
interrupted by reasonable concerns. This brings us back to 
clinical naivety of the TRICC trial. Effort for the formal con-
duction of MINT trial is ongoing, without important protocol 
modifications with the exception of encouraging transfusion 
in Hb <7g/dl, There are accompanying public concerns about 
ethics and adequacy of information in the consent form.37,38 
Maybe investigators consider cardiac disease as a challenge, 
but pilot data, even in the face of group dissimilarities are 
disappointing. As for general ICU patients, they are prone to 
have underestimated coronary artery disease and should not 
be left to elude in the otherwise noisy general critical context.
f. Meta-analytic progress in the mean time
Systematic reviews39,40 in general suffer from inadequate 
homogeneity in this field. Cochrane and Holst’s metanalyses, 
although without retrospective element included, function 
more as aggregates of various studies in terms of kind and qual-
ity. More sophisticated statistical methods (e.g. trial sequence 
technique in Holst et al paper in BJM) do not guarantee level 
of evidence establishment, as they deal with statistical but not 
clinical inhomogeneity. Salpeter’s effort41 is focused exclusively 
on achieving homogeneity but this does not seem to be ac-
complished as studies like TRICC and villanueva study are 
obviously dissimilar in terms of patient populations included. 
All reviews point to restrictive strategy as most proper but 
this comes up more as a result of preformed author volition 
and less as an unbiased arithmetic result which is the main 
issue in gathering studies together. The specific category of 
cardiovascular disease has been addressed in the metanalysis 
by Docherty and Walsh, where a more lenient threshold is 
proposed, albeit unitizing again disparate proportions of 
patients coming from miscellaneous studies, all before 2013.42
The most obvious aspect of bias is timing of publication as 
this always coincides with the arrival of restriction encouraging 
studies. TRICC remains the cornerstone of all these metana-
lytical efforts. It would be certainly preferable to reproduce 
the results of TRICC with another study with general patient 
population. Currently, TRISS resembles TRICC more than 
every other study but again it is focused only on sepsis patients. 
Maybe also the combination of Titre-2 with TRICS III can 
offer a degree of support. Based on a combination of TRICC 
with systemic reviews of studies with modest homogeneity, 
the achieved level of evidence is considered to be presented 
as 1b. To upgrade to 1a, or even to stabilize 1b means at 
least another study like TRiCC. Threshold of 7g/dl may be 
in the mean time applied and evaluated inside the ICU but 
is not subject to extrapolations to other patient populations 
approaching, like perioperative patients.43
3 .  C o n C l u S i o n
First priority must be to preserve an adequate minimum 
level of hemoglobin concentration instead of full restoration. 
Presence of anemia influences outcome but transfusion should 
be regarded too complicated as a solution. As full Individu-
alization of the indication for transfusion is rather immodest 
as a uniform hospital proposal,4,44 we need a general direction 
represented by the triggering threshold suggestion. Applicabil-
ity of restriction thresholds depends on respect on appropriate-
ness, critical illness staging and estimation of comorbidities.45-47 
The rule of 7 g/dl seems to be well supported for the time 
being, although not irrevocably proven. Sensitive subpopula-
tions pointed out by scientific associations12 still hold, with 
the exception of early septic patients which can cope with 
low threshold and growing worries about cardiovascular 
patients. Clinical investigation concerns are more reliable 
to steer transformations of routine practice than statistical 
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formatting. Both are needed though to substantiate indisput-
able evidence. Improvements in a wide array of therapeutic 
protocols have surpassed liberal hemoglobin goals and should 
be incorporated in hospital practice throughout the world. 
Intensive care units offer multidisciplinary monitoring 
and therapy. This should not be over-interpreted, as we think 
that is happening with the ‘new normal’ concept.48 Non critical 
patients most often can’t tolerate a hemoglobin value fall to 7 
g/dl either acute or chronic. Thresholds like this are excessively 
austere in the face of jeopardized reserves and must be tightly 
anchored with sufficient scientific data and supporting frame. 
Our clinical approach as to symptoms and signs interpretation 
is anticipated to change. Interestingly, ultimate consequences 
of critical illness like cognitive dysfunction, persistent paralysis 
due to neuromyopathy or non-healing pressure ulcers have not 
been studied in connection to transfusion tactics met in the first 
place.49 At present, a descent compromise has been reached 
between blood resources use rationalization, evidence base 
medicine principles compliance and critical illness causality. 
Like pharmacologic investigations in the post marketing stage, 
conservative thresholds need now to be stabilized, consistently 
applied and globally evaluated for a significant period of time.50
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